N4 Pharma Welcomes New Board Expertise
Company Announcements

N4 Pharma Welcomes New Board Expertise

N4 Pharma (GB:N4P) has released an update.

N4 Pharma PLC, a specialist pharmaceutical company, has announced the appointment of Dr. Michael Palfreyman as an independent Non-Executive Director. Dr. Palfreyman brings over four decades of drug discovery and development experience, having held significant roles in major pharmaceutical companies and biotech startups, and is expected to contribute greatly to N4 Pharma’s efforts to commercialize their novel delivery system, Nuvec®.

For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskN4 Pharma Reports Progress in Gene Delivery Tech
TipRanks UK Auto-Generated NewsdeskN4 Pharma Appoints New Auditor, Eyes Partnerships
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App